促红细胞生成素与肾性贫血研究进展

被引:9
作者
张燕京
李晓玫
机构
[1] 北京大学第一医院肾内科暨北京大学肾脏病研究所
关键词
肾疾病; 贫血; 红细胞生成素;
D O I
暂无
中图分类号
R692.5 [肾功能衰竭];
学科分类号
摘要
肾性贫血的最主要原因是促红细胞生成素 (EPO)缺乏。人类重组促红细胞生成素 (rHuE PO)应用于临床后 ,明显改善了终末期肾脏病病人的临床症状和生活质量。本文就EPO的生理、病理特征和rHuEPO的临床应用现状及研究进展作一综述
引用
收藏
页码:852 / 857
页数:6
相关论文
共 22 条
[1]  
Pathophysiology of renal anem ia. EckardtKU. C lin Nephrol . 2000
[2]  
Erythropoietin: Physiologic and Pharmacologic Aspects. Fisher JW. Proceedings of the Society for Experimental Biology and Medicine . 1997
[3]  
Erythropoietin: multiple physiological functions and regulation of biosynthesis. Sasaki R,Masuda S,Nagao M. Bioscience Biotechnology and Biochemistry . 2000
[4]  
Nitric oxide enhancement of erythropoietin production in the isolated perfused rat kidney. Yoshioka K,Fisher JW. American Journal of Physiology . 1995
[5]  
Endogenous nitric oxide attenuates erythropoietin gene expression in vivo. Todorov V,Gess B,Godecke A,et al. Pflügers Archiv European Journal of Physiology . 2000
[6]  
Erythropoietin:physiology and pharmacology up- date. Fisher JW. ExpBiol Med(Maywood) . 2003
[7]  
Overview: erythropoiesis, anemia, and the impact of erythropoietin. Gabrilove J. Seminars in Hematology . 2000
[8]  
Erythropoietin in the central nervous system, and its use toprevent hypoxic-ischemic brain damage. Juul S. Acta paediatrica Supplement . 2002
[9]  
Erythropoietin, iron metabolism, and red blood cell production. Adamson J. Seminars in Hematology . 1996
[10]  
Comparison of plasma erythropoietin concentrations and iron status in hemodialyzed patients not requiring and requiring rHuEpo therapy. Majdan M,Ksiazek A,Koziol M,et al. Nephron . 1996